Jean-Christophe Bourdon

+44 (0)1382 383285
Senior Lecturer


Dr. Jean-Christophe Bourdon did his PhD research project on p53 under the co-supervision of Prof Brigitte Debuire and Dr Evelyne and Pierre May, co-discoverer of p53. He earned his Ph.D in Cellular and Molecular Biology in 1997 at Paris XI University, France.

Dr Bourdon joined in 1998 David Lane's lab, co-discoverer of p53 at the University of Dundee, Scotland. He became University Senior Research Fellow in 2005 and co-director of the Inserm-European Associated Laboratory, co-directed by Dr Anne-Catherine Prats (Toulouse University, France) in 2006. In April 2010, he was appointed Senior Lecturer at the College of Medicine at Dundee University, position that he presently held. In June 2012, he was awarded the prestigious fellowship from Breast Cancer Campaign.

For his ResearchGate profile, click here and for his Google Scholar profile (JC Bourdon), click here.


Dr Bourdon established during his Ph.D in 1997 that p53 responsive elements are composed of clusters of DNA sequence RRRCWWGYYY. He validated this consensus sequence for p53 response element by identifying several p53 target genes. Joining the David Lane’s laboratory, he characterised a new p53-inducible pro-apoptotic gene that he named Scotin (also named Shisa-5). Scotin is a transmembrane protein that triggers apoptosis in a caspase dependent manner in response to DNA damage and Endoplasmic reticulum stress.

Dr Bourdon demonstrated that the human p53 gene encodes 12 different p53 protein isoforms (containing different domains) due to alternative splicing, alternative initiation of translation and alternative promoter usage (1) and that the dual gene structure of the p53 gene family is conserved through evolution from Drosophila to man. His research group demonstrated that p53 isoforms are associated with cancer patient prognosis. They established that p53 isoforms regulate cell response to damage modulating cell cycle progression, senescence, differentiation, cell death, angiogenesis, endothelial and tumour cell migration. The aims of his research group are 1- to characterise the biological activities of the p53 isoforms in cancer, particularly in breast cancer, 2- to establish regulation of p53 isoforms expression at the mRNA (splicing, internal promoter) and protein levels (proteasome degradation), 3- to define p53 isoform as predictive treatment biomarkers (personalised treatment) and 4- to develop new drugs that modulate p53 protein isoform expression in order to control cell response to cancer treatment.

PhD supervision

Sebastien Jo, 'Regulation of P53 Isoforms expression to take control of the cell fate outcome in response to cellular stree', 2013.

Marie P. Khoury, Identification of p53 isoforms and characterisation of their biological activities in cancer and normal cells, 2010

Hugo Bernard, Role of p53 and its isoforms in the expresson of FGF-2 and tumoral neavascularisation, 2010

Hayley C. Moore, The DEAD-Box protein p68: a coactivator of p53 and regulator of p53 isoform expression, 2009

Fiona Murray-Zmijewski, The regulation of p53’s internal promoter and characterisation of the p53 isoforms, 2007

Lectures and conferences

Invited by the French Embassy in London, as one of 150 most influent French citizens in the UK to meet French President de la Republique, Mr Francois Hollande, in July 2012.

Invited in January 2013 by Mrs Samantha Cameron at 10 Downing Street as a Fellow of Breast Cancer Campaign to discuss Breast Cancer Research with influential donators, patients, politics, journalists.

Public address in June 2013 to the participants of Moon-Walk Edinburgh (4000 people)

He organised the following international conferences:

Organiser of the Cancer Alliance conference Toulouse/Dundee Universities in March 2006 in Toulouse (France)

Organiser of the Cancer Alliance conference Toulouse/Dundee Universities in June 2008 in Dundee (UK).

Organiser of the first International p53 isoform workshop in September 2010 in Lyon (France)

Keynote lecture:

Lawrence Berkeley National Laboratory Mina Bissell, San Francisco, June 2013

University of California San-Francisco (UCSF) Alan Balmain, San Francisco, June 2013

Eurocancer 2011, Palais des Congres, Paris, 21-23 June 2011, France

1st international Protein kinase regulating RNA splicing workshop 12-16 November 2011, Roscoff, France

The Nordic Network on p53 and Cell Cycle Regulation conference 2007 June 15-17, 2007 in Bergen, Norway.

Invited speaker:

16th international p53 workshop, 15-19 June 2014, Stockholm, Sweden

5th international MDM2 workshop, 16th-19th October 2011, New-York, USA

5th international p63/p73 workshop, 12-14 September, 2011, Lyon -France

5th mutant p53 workshop, 22-25 May, 2011, Ariccia-Italy

15th international p53 workshop, 8-12 October 2010, Philadelphia, USA

1st international p53 isoform meeting, 13-15 September 2010, Lyon, France

EORTC-PAMM, 27-30 January 2010, Toulouse, France

SBMCTA, IX Congress-2009, 11-14 November 2009, Ouro Preto, Brazil

IV Fundamental aspects of DNA repair and Mutagenesis 8-10 November 2009, Belo Horizonte, Brazil

Workshop 3R, les 3R comme signature péjorative de la maladie, 10-11 March 2009, Toulouse, France

SBMCTA, IX Congress-2009, 11-14 November 2009, Ouro Preto, Brazil

p53, microRNA and Cancer 10th December 2008, Leicester, UK

14th international p53 workshop, 27-31 October 2008, Shanghai, China

2nd meeting Dundee Toulouse Cancer Research Alliance, June 12-14, 2008, Dundee, UK

3rd International Workshop on Mutant p53, 13-15 November 2007, Lyon, France

First meeting German ~ French Meeting. DNA Repair, Damage Signaling and Carcinogenesis. September 15-19, 2007, Toulouse, France

3rd international p63/p73 workshop 18-21 March, 2007, Rome -Italy

13th international p53 workshop, 20-24 May 2006., New-York, USA

First meeting Dundee Toulouse Cancer Research Alliance March 23 – 25, 2006, Toulouse, France

Benzon Symposium No. 52, Cellular Responses to DNA Damage August 22-25, 2005, Copenhagen, Denmark

12th international p53 workshop, 6-10 November 2004., Dunedin, New-Zealand

2nd international p73/p63 workshop 25-27 March 2004, Rome, Italy

Effects of p53 on gene expression. The fourth International SASS conference, Apoptosis in Cancer and Infection, 6-10 October 2002, Capri, Italy


59 publications (Original Research articles, book chapter, Review).

41 publications since January 2007to present:

Total citation: 3136 (Google Scholar)

h-index: 28

m-index (h-index/18years career) : 1.5

Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Surget S, Khoury MP, Bourdon JC. Onco Targets Ther. 2013 Dec 19;7:57-68.

Influenza NS1 interacts with p53 and alters its binding to p53-responsive genes, in a promoter-dependent manner. Terrier O, Diederichs A, Dubois J, Cartet G, Lina B, Bourdon JC, Rosa-Calatrava M. FEBS Lett. 2013 Sep 17;587(18):2965-71. doi: 10.1016/j.febslet.2013.08.006. Epub 2013 Aug 13

p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Marcel V, Ghayad SE, Belin S, Therizols G, Morel AP, Solano-Gonzàlez E, Vendrell JA, Hacot S, Mertani HC, Albaret MA, Bourdon JC, Jordan L, Thompson A, Tafer Y, Cong R, Bouvet P, Saurin JC, Catez F, Prats AC, Puisieux A, Diaz JJ. Cancer Cell. 2013 Sep 9;24(3):318-30.

Mutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes. Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais C, Bourdon JC, Huerre M, Londono-Vallejo A, Toledo F. Cell Rep. 2013 Jun 27;3(6):2046-58. doi: 10.1016/j.celrep.2013.05.028. Epub 2013 Jun 13.

p53 protein isoforms: key regulators in the front line of pathogen infections? Terrier O, Bourdon JC, Rosa-Calatrava M. PLoS Pathog. 2013 Apr;9(4):e1003246. doi: 10.1371/journal.ppat.1003246. Epub 2013 Apr 4.

Expression of TP53 isoforms p53? or p53? enhances chemosensitivity in TP53(null) cell lines. Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. PLoS One. 2013;8(2):e56276. doi: 10.1371/journal.pone.0056276. Epub 2013 Feb 11.

Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a. Terrier O, Textoris J, Carron C, Marcel V, Bourdon JC, Rosa-Calatrava M. J Gen Virol. 2013 May;94(Pt 5):985-95. doi: 10.1099/vir.0.049528-0. Epub 2013 Jan 23.

Detecting p53 isoforms at protein level. Marcel V, Khoury MP, Fernandes K, Diot A, Lane DP, Bourdon JC. Methods Mol Biol. 2013;962:15-29. doi: 10.1007/978-1-62703-236-0_2.

Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Khoury MP, Marcel V, Fernandes K, Diot A, Lane DP, Bourdon JC. Methods Mol Biol. 2013;962:1-14. doi: 10.1007/978-1-62703-236-0_1.

Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. Dichtel-Danjoy ML, Ma D, Dourlen P, Chatelain G, Napoletano F, Robin M, Corbet M, Levet C, Hafsi H, Hainaut P, Ryoo HD, Bourdon JC, Mollereau B. Cell Death Differ. 2013 Jan;20(1):108-16. doi: 10.1038/cdd.2012.100. Epub 2012 Aug 17.

p53 is activated in response to disruption of the pre-mRNA splicing machinery. Allende-Vega N, Dayal S, Agarwala U, Sparks A, Bourdon JC, Saville MK. Oncogene. 2013 Jan 3;32(1):1-14. doi: 10.1038/onc.2012.38. Epub 2012 Feb 20.

The p53 isoform, ?133p53?, stimulates angiogenesis and tumour progression. Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC, Prats AC. Oncogene. 2013 Apr 25;32(17):2150-60. doi: 10.1038/onc.2012.242. Epub 2012 Jun 25.

Influenza A viruses control expression of proviral human p53 isoforms p53? and Delta133p53?. Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC. J Virol. 2012 Aug;86(16):8452-60. doi: 10.1128/JVI.07143-11. Epub 2012 May 30.

The p53 isoforms are differentially modified by Mdm2. Camus S, Ménendez S, Fernandes K, Kua N, Liu G, Xirodimas DP, Lane DP, Bourdon JC. Cell Cycle. 2012 Apr 15;11(8):1646-55. doi: 10.4161/cc.20119. Epub 2012 Apr 15.

Diverse p63 and p73 isoforms regulate ?133p53 expression through modulation of the internal TP53 promoter activity. Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC. Cell Death Differ. 2012 May;19(5):816-26. doi: 10.1038/cdd.2011.152. Epub 2011 Nov 11.

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Ånensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Hovland R, Taskén K, Knappskog S, Lønning PE, Bruserud Ø, Gjertsen BT. Oncogene. 2012 Mar 22;31(12):1533-45. doi: 10.1038/onc.2011.348. Epub 2011 Aug 22.

Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P, Bourdon JC. Cell Death Differ. 2011 Dec;18(12):1815-24. doi: 10.1038/cdd.2011.120. Epub 2011 Sep 23. Review.

Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. Terrier O, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N'guyen C, Lina B, Diaz JJ, Bourdon JC, Rosa-Calatrava M. Virol J. 2011 Jun 8;8:285. doi: 10.1186/1743-422X-8-285.

Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Watt SA, Pourreyron C, Purdie K, Hogan C, Cole CL, Foster N, Pratt N, Bourdon JC, Appleyard V, Murray K, Thompson AM, Mao X, Mein C, Bruckner-Tuderman L, Evans A, McGrath JA, Proby CM, Foerster J, Leigh IM, South AP. Oncogene. 2011 Nov 17;30(46):4666-77. doi: 10.1038/onc.2011.180. Epub 2011 May 23.

An evolutionarily conserved, alternatively spliced, intron in the p68/DDX5 DEAD-box RNA helicase gene encodes a novel miRNA. Moore HC, Johnston M, Nicol SM, Bourdon JC, Thompson AM, Hutvagner G, Fuller-Pace FV. RNA. 2011 Apr;17(4):555-62. doi: 10.1261/rna.2591611. Epub 2011 Feb 23.

p53 Isoforms: An Intracellular Microprocessor? Khoury MP, Bourdon JC. Genes Cancer. 2011 Apr;2(4):453-65. doi: 10.1177/1947601911408893.

p53 mutant breast cancer patients expressing p53? have as good a prognosis as wild-type p53 breast cancer patients. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM. Breast Cancer Res. 2011 Jan 20;13(1):R7. doi: 10.1186/bcr2811.

Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Dalvai M, Mondesert O, Bourdon JC, Ducommun B, Dozier C. Oncogene. 2011 May 12;30(19):2282-8. doi: 10.1038/onc.2010.588. Epub 2011 Jan 17.

First International p53 Isoforms Meeting: 'p53 isoforms through evolution: from identification to biological function'. Marcel V, Olivier M, Mollereau B, Hainaut P, Bourdon JC. Cell Death Differ. 2011 Mar;18(3):563-4.

Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, Vojtesek B, Bourdon JC, Lane DP, Harris CC. Nat Cell Biol. 2010 Dec;12(12):1205-12. doi: 10.1038/ncb2123. Epub 2010 Nov 7.

p53-dependent repression of polo-like kinase-1 (PLK1). McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW. Cell Cycle. 2010 Oct 15;9(20):4200-12. Epub 2010 Oct 4.

?160p53 is a novel N-terminal p53 isoform encoded by ?133p53 transcript. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S, Bourdon JC. FEBS Lett. 2010 Nov 5;584(21):4463-8. doi: 10.1016/j.febslet.2010.10.005. Epub 2010 Oct 13.

The RNA helicase p68 modulates expression and function of the ?133 isoform(s) of p53, and is inversely associated with ?133p53 expression in breast cancer. Moore HC, Jordan LB, Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon JC, Fuller-Pace FV. Oncogene. 2010 Dec 9;29(49):6475-84. doi: 10.1038/onc.2010.381. Epub 2010 Sep 6.

p53 directly transactivates ?133p53?, regulating cell fate outcome in response to DNA damage. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC. Cell Death Differ. 2011 Feb;18(2):248-58. doi: 10.1038/cdd.2010.91. Epub 2010 Aug 6.

DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Lemée F, Bergoglio V, Fernandez-Vidal A, Machado-Silva A, Pillaire MJ, Bieth A, Gentil C, Baker L, Martin AL, Leduc C, Lam E, Magdeleine E, Filleron T, Oumouhou N, Kaina B, Seki M, Grimal F, Lacroix-Triki M, Thompson A, Roché H, Bourdon JC, Wood RD, Hoffmann JS, Cazaux C. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13390-5. doi: 10.1073/pnas.0910759107. Epub 2010 Jul 12.

The isoforms of the p53 protein. Khoury MP, Bourdon JC. Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000927. doi: 10.1101/cshperspect.a000927. Review.

p53 family members in cancer diagnosis and treatment. Machado-Silva A, Perrier S, Bourdon JC. Semin Cancer Biol. 2010 Feb;20(1):57-62.

p53 mutation, deprivation and poor prognosis in primary breast cancer. Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell LJ, McCowan C, Bourdon JC, Purdie CA, Jordan LB, Dewar JA, Wu L, Thompson AM. Br J Cancer. 2010 Feb 16;102(4):719-26. doi: 10.1038/sj.bjc.6605540. Epub 2010 Jan 26.

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon JC, Lane DP, Harris CC. Nat Cell Biol. 2009 Sep;11(9):1135-42. doi: 10.1038/ncb1928. Epub 2009 Aug 23.

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J. Genes Dev. 2009 Feb 1;23(3):278-90. doi: 10.1101/gad.1761609.

p53 Family isoforms. Bourdon JC. Curr Pharm Biotechnol. 2007 Dec;8(6):332-6. Review.

Scotin: A new p63 target gene expressed during epidermal differentiation. Zocchi L, Bourdon JC, Codispoti A, Knight R, Lane DP, Melino G, Terrinoni A. Biochem Biophys Res Commun. 2008 Mar 7;367(2):271-6.

The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum membrane. Draeby I, Woods YL, la Cour JM, Mollerup J, Bourdon JC, Berchtold MW. Arch Biochem Biophys. 2007 Nov 1;467(1):87-94. Epub 2007 Aug 21.

p53 and its isoforms in cancer. Bourdon JC. Br J Cancer. 2007 Aug 6;97(3):277-82. Epub 2007 Jul 17. Review.

Expression of novel p53 isoforms in oral lichen planus. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K. Oral Oncol. 2008 Feb;44(2):156-61. Epub 2007 Apr 5.


Draeby I, Woods YL, la Cour JM, Mollerup J, Bourdon JC, Berchtold MW.

The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum membrane.

Arch Biochem Biophys. 2007 Nov 1;467(1):87-94. (cited 13, April 2014)

Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K.

Expression of novel p53 isoforms in oral lichen planus.

Oral Oncol. 2008 Feb;44(2):156-61. Epub 2007 Apr 5 (cited 41, April 2014)

Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K.

Expression of p53 isoforms in squamous cell carcinoma of the head and neck.

Eur J Cancer. 2007 Feb;43(3):617-23. (cited 63, April 2014)

Bourdon JC

p53 Family isoforms.

Curr Pharm Biotechnol. 2007 Dec;8(6):332-6.

JC Bourdon

p53 and its isoforms in cancer.

Br J Cancer. 2007 Jul 31;97(3):277-82. Epub 2007 Jul 17.


Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT.

A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.

Clin Cancer Res. 2006 Jul 1;12(13):3985-92.

Dudgeon C, Kek C, Demidov ON, Saito S, Fernandes K, Diot A, Bourdon JC, Lane DP, Appella E, Fornace AJ Jr, Bulavin DV.Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.

Cancer Res. 2006 Mar 15;66(6):2928-36.

Murray-Zmijewski F, Lane DP, Bourdon JC.

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

Cell Death Differ. 2006 Jun;13(6):962-72.


Book chapter:

JC Bourdon and DP. Lane

p53 family pathway in cancer

2nd Edition of The Cancer Handbook. JOHN WILEY & SONS LIMITED




Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity.

Genes Dev. 2005 Sep 15;19(18):2122-37.


Bates G., Nicol S., Wilson B., Bourdon JC., Wardrop J., Gregory D., Lane D., Perkins N., Fuller-Pace F.

The DEAD box protein p68: a novel transcriptional co-activator of the p53 DNA damage response

EMBO J. 2005 Feb 9;24(3):543-53.




Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, Woods YL, Lane DP.

Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo.

J Biol Chem. 2004 Oct 1;279(40):42169-81


Xirodimas D., Saville M., Bourdon JC, Hay R and Lane D. P.

MDM2-mediated neddylation of p53 inhibits its transcriptional activity.

Cell. 2004 Jul 9;118(1):83-97.

Paitel E, Sunyach C, Alves da Costa C, Bourdon JC, Vincent B, Checler F.

Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels.

J Biol Chem. 2004 Jan 2; 279(1): 612-8.




Tullo A, Mastropasqua G, Bourdon JC, Centonze P, Gostissa M, Costanzo A, Levrero M, Del Sal G, Saccone C, Sbisà E.

Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target.

Oncogene. 2003 Nov 27;22(54):8738-48.


Bourdon JC, Laurenzi VD, Melino G, Lane D.

p53: 25 years of research and more questions to answer.

Cell Death Differ. 2003 Apr;10(4):397-9.




Bourdon JC., Renzing J., Robertson P., Fernandes K. and Lane D.P

Scotin, a novel ER-located pro-apoptotic protein, is directly transactivated by p53

J Cell Biol. 2002 Jul 22;158(2):235-46.




Deguin-Chambon V, Vacher M, Jullien M, May E, Bourdon JC.

Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis.

Oncogene. 2000 Nov 30;19(51):5831-41.


Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P.

Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis.

J Biol Chem. 2000 Feb 11; 275(6):3867-72. (cited 82, August 2010)


Nylander K, Bourdon JC, Bray SE, Gibbs NK, Kay R, Hart I, Hall PA.

Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response.

J Pathol. 2000 Jan; 190(1): 39-46.


Bourdon JC., Deguin-Chambon V., Lelong J-C., Dessen P., May P., Debuire B. and May E.

Further characterisation of the p53-responsive element –identification of new candidate

genes for transactivation by p53.

Oncogene, 14: 85-94 (1997)


Bourdon JC., D'Errico A., Paterlini P., Grigioni W.F., May E., Debuire B. P53 protein accumulation in relation to gene mutation in European hepatocellular carcinomas.

Gastroenterology, 106: 1176-1182 (1995)

Patents: (5)

Signature for the diagnosis of breast cancer aggressiveness and genetic instability

C Cazaux, J Hoffmann, J Bourdon, M Da, S Alice, H Roche

EP Patent 2,499,258 (2012), EP Patent 2,322,658, US Patent App. 13/110,749, WO Patent 2,011,058,143


Method for improving the production of influenza viruses and vaccine seeds

O Terrier, jc Bourdon, m Rosa-Calatrava

WO patent 2,012,059,696 (2012), US Patent App. 13/883,310 (2011)


Method for testing a subject thought to be predisposed to having cancer

P Roux, G Gadea, S Vinot, C Anguille, J Bourdon, K Fernandes

EP Patent 2,272,979 (2011), WO Patent 2,011,000,891


Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer

CC Harris, K Fujita, I Horikawa, B Vojtesek, J Bourdon, DP Lane

WO patent 2,009,064,590 (2009), EP patent 2,217,706 (2010),



DP Lane, J Bourdon, J Renzing

EP Patent 1,362,100,: WO 02/068465 (2003)